Gland Pharma Clears USFDA Inspection with Zero Observations
Gland Pharma’s Visakhapatnam sterile oncology and API facilities successfully completed a USFDA GMP inspection with zero Form 483 observations, highlighting its strong commitment to manufacturing quality and regulatory compliance.
- Hormonal Health
- Manufacturing
- Research & Development
Gland Pharma has achieved a significant regulatory milestone with its Visakhapatnam facilities completing a US Food and Drug Administration (USFDA) Good Manufacturing Practices (GMP) inspection with zero Form 483 observations.
The inspection covered the company’s sterile oncology and Active Pharmaceutical Ingredient (API) manufacturing facilities in Visakhapatnam. The absence of Form 483 observations indicates that the facilities did not receive any inspectional findings requiring formal documentation by the USFDA.
This outcome reinforces Gland Pharma’s focus on maintaining high manufacturing standards, robust quality systems and regulatory compliance across its operations. For pharmaceutical manufacturers supplying regulated international markets, successful regulatory inspections are an important indicator of consistent quality and adherence to GMP requirements.
The development also strengthens confidence in Gland Pharma’s manufacturing capabilities and its ability to meet stringent global regulatory expectations. Zero observations from a USFDA inspection represents a positive milestone for the company and its continued focus on quality-driven pharmaceutical manufacturing.
Zafieon Insights carries Zafieon Pharma's own perspective on its focus, its quality framework and its manufacturing partnerships. It is not medical advice, it does not describe any product's indications, benefits or effects, and it is not a substitute for professional medical judgement.
Continue reading
- Women's Health
- Gynaecology
Novartis Signs Up to $3.2 Billion Deal with Alteogen for Drug-Delivery Technology
Novartis has entered a deal worth up to $3.2 billion with South Korea’s Alteogen to access advanced drug-delivery technology that could enable certain intravenous medicines to be developed as more convenient injectable formulations.
Read- Manufacturing
- Pharmaceutical Industry
cipla and Qilu Pharmaceutical Partner to Advance Keytruda Biosimilar in the U.S.
Cipla has partnered with China’s Qilu Pharmaceutical to bring QL2107, a biosimilar of Merck’s leading cancer immunotherapy Keytruda, to the U.S. market, strengthening its presence in the growing oncology and biosimilars segment.
Read- Nutraceuticals
- Women's Health
Sun Pharma Reaches U.S. Drug-Pricing Agreement, Strengthening Global Market Access
Sun Pharmaceutical Industries has joined a new group of pharmaceutical companies agreeing to provide medicines to U.S. state Medicaid programs at Most-Favoured-Nation pricing, highlighting the evolving landscape of global drug pricing and market access.
Read